(A) Genetic model of KRT18-CreERT2:Rosa26-lox-STOP-lox-TdTomato mouse system. (B) Representative gating of TdTomato expression in negative control (left: Genotype: Krt18-CreERT2+) and tamoxifen-induced positive control (right: Genotype: KRT18-CreERT2+: Rosa26-lox-STOP-lox-TdTomato+/-). Percent of bone marrow (BM) (C) hematopoietic stem and progenitor cell (HSPC), (D) HSC, (E) CD41+ HSC, and (F) myeloid populations that are TdTomato+. Percent of BM (G) total monocytes, (H) granulocytes, (I) granulocyte/monocyte progenitor (GMP), (J) BM T cells, and (K) BM B cells that are TdTomato+. Percent of peripheral blood (PB) (L) total myeloid cells, (M) monocytes, (N) granulocytes, (O) T cells, and (P) B cells that are TdTomato+. Data representative of three independent experiments; (C–N) n = 5–7 mice/group. Statistical comparison done using unpaired t-tests; *p < 0.05, **p < 0.01.
Figure 3—source data 1. Levels of newly generated cells in response to GAS infection.